FKBP5 methylation predicts treatment response in major depressive disorder

Andreas Menke
DOI: https://doi.org/10.1016/j.psyneuen.2023.106705
IF: 4.693
2024-02-01
Psychoneuroendocrinology
Abstract:Background Genetic and environmental factors, mainly exposure to adverse life events, shape the risk for stress- related mental disorders such as major depressive disorder (MDD). These two factors likely converge on a molecular level to alter the glucocorticoid signaling. FKBP5 is a major endogenous regulator of the stress- neuroendocrine system. Methods Patients with major depression as well as healthy controls underwent a modified dexamethasone suppression test (mDST), with blood withdrawals at 18:00 and 3hours after 1.5mg dexamethasone ingestion. FKBP5 methylation and whole blood mRNA expression pre and post glucocorticoid receptor (GR)-stimulation with dexamethasone in dependence of the SNP rs1360780 were analyzed. Subjects were evaluated using the Hamilton Depression Rating Scale (HAMD), the Childhood Trauma Questionnaire (CTQ) and the List of Threatening Experiences (LTE) amongst others. Results GR-stimulation led to a significant SNP-dependent demethylation of FKBP5 and to a significant increase of FKBP5-mRNA in all subjects. FKBP5-methylation levels were significantly lower pre and post GR-stimulation in MDD responders to antidepressants compared to non-responders. In addition, severe life events occurring prior to MDD development significantly impaired both response to antidepressants and stress-response systems. Conclusions We found FKBP5 methylation associated with treatment response in MDD. In addition, we found that not only childhood trauma, but also severe life events substantially impact treatment response and the function of the glucocorticoid signaling.
neurosciences,endocrinology & metabolism,psychiatry
What problem does this paper attempt to address?